Revenue Update on Repligen Corporation(NASDAQ:RGEN)

Repligen Corporation(NASDAQ:RGEN) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $25.599M. Analysts estimated a revenue of $24.050M. The revenues were 6.44% above the estimates. Earnings per share were $0.08. The reported EPS was above estimates by 14.29%. Analysts had estimated an EPS of $0.07.

Repligen Corporation (RGEN) made into the market gainers list on Wednesdays trading session with the shares advancing 6.04% or 1.84 points. Due to strong positive momentum, the stock ended at $32.32, which is also near the day’s high of $32.42. The stock began the session at $30.75 and the volume stood at 5,39,077 shares. The 52-week high of the shares is $34.06 and the 52 week low is $21.11. The company has a current market capitalization of $1,093 M and it has 3,38,31,867 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Nov 29, 2016, Anthony Hunt (Chief Executive Officer) sold 5,000 shares at $33.12 per share price.Also, On Sep 16, 2016, Thomas F Jr Ryan (director) sold 2,700 shares at $32.58 per share price.On May 19, 2015, James R Rusche (Senior Vice President) sold 15,000 shares at $41.32 per share price, according to the Form-4 filing with the securities and exchange commission.

Repligen Corporation (Repligen) is a life sciences company. The Company develops manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A critical reagents used in biomanufacturing to purify monoclonal antibodies which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns as well as media and quality test kits and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.

Add Comment